The company's S-1 lays the groundwork for what is widely expected to be one of the largest initial public offerings of the year, second only to Uber's IPO in May. It's also...Technologyread more
Fraud investigator Harry Markopolos' accusations extended beyond GE's management to actuaries, auditors and analysts who he claims overlooked billions in liabilities.Marketsread more
Trump's tweet comes a day after Apple put out a press release describing the money it spends on U.S.-based suppliers and vendors.Technologyread more
CNBC combed through Wall Street research to see which stocks are still a buy after their earnings reports.Marketsread more
President Donald Trump held a call on Wednesday with the CEOs of three major U.S. banks, according to people with knowledge of the situation.Marketsread more
Despite aggressive strides, Waymo needs one thing before their self-driving cars become a seriously useful transportation system: people. We talked to the ones closest to it.Technologyread more
Scientists say the smoke plumes, filled with megatons of tiny, harmful particles, could travel to other areas of the world and cause serious respiratory problems for people.Weather & Natural Disastersread more
Some Weight Watchers loyalists applaud Kurbo by WW. But nutritionists worry Kurbo promotes an unhealthy relationship with food during an especially impressionable time.Health and Scienceread more
Benefits from what President Trump called "the biggest reform of all time" to the tax code have dwindled to a faint breeze just 20 months after its enactment, writes John...Politicsread more
Epstein, 66, was found in his cell in Manhattan federal lockup Saturday morning and transferred to a nearby hospital, where he was subsequently pronounced dead.Politicsread more
Air travelers faced delays at U.S. airports on Friday afternoon after a computer issue snarled processing of international arrivals.Airlinesread more
The Trump administration has withdrawn its proposal to eliminate rebates from government drug plans, a key component of the president's blueprint to lower prescription drug prices, a White House spokesman confirmed.
"Based on careful analysis and thorough consideration, the President has decided to withdraw the rebate rule," White House spokesman Judd Deere said in an emailed statement Thursday.
The administration sought to ban discounts on prescription drugs that insurers negotiate with pharmaceutical companies, saying these "backdoor rebates" have led to a "perverse incentive" for drugmakers to set list prices on drugs artificially high. Instead, the rule would give pharmacy benefit managers a flat fee for including drugs on their plan and would allow discounts to be passed on to patients at the pharmacy counter.
Health and Human Services Secretary Alex Azar touted the plan as a way to "bring real transparency to drug markets and deliver savings directly to patients when they walk into the pharmacy." However, the Congressional Budget Office found the rule would cost $177 billion through 2029.
Insurers opposed the proposal, saying it would not accomplish its goal of lowering prescription drug prices.
CVS in a statement said it is "pleased" with the administration's move and that "any solution should start with addressing drug prices."
Axios reported the news earlier.
Deere said the Trump administration is "encouraged by continuing bipartisan conversations about legislation" to lower prescription drug costs and the president "will consider using any and all tools" to ensure drug prices decline.
— CNBC's Bertha Coombs contributed to this report.